secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001104659-24-033726
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics names Toby Ferguson as Chief Medical Officer
-----------------------------------------------------------------

- Employment starts March 25, 2024; base salary $485,000, target bonus 40%.
- Granted inducement option for 210k shares and RSU for 105k shares, both time-vesting.
- Dr. Ferguson previously VP, Head of Neuromuscular Development at Biogen (2013-2024).
- Severance provides 12 months base salary and pro-rata bonus if terminated without cause or for good reason within 12 months post sale event.
- At-will employment; standard non-compete and confidentiality obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924033726/0001104659-24-033726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465924033726/tm247944d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer